SEC Form 4 · accession 0000899243-17-012364
Altimmune, Inc. · ALT
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Sybil Tasker
Officer — See Remarks
Period of report
May 4, 2017
Accepted (ET)
May 8, 2017 · 8:37 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001326190
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Options (option to buy)F2,F1 | $13.38 | May 4, 2017 | A | 48,691 | A | — | Apr 7, 2026 | Common Stock, par value $0.0001 | 48,691 | 48,691 | D |
Explanation of responses
- F1The option is currently exercisable to purchase 16,250 shares of the Issuer's common stock, par value $0.0001. An additional 25% of the option will vest on each of 4/8/2018, 4/8/2019, and 4/8/2020.
- F2Acquired pursuant to the Agreement and Plan of Merger, dated as of January 18, 2017 (as amended on March 29, 2017, the "Merger Agreement"), pursuant to which a wholly-owned subsidiary of the Issuer merged with and into Altimmune, Inc. ("Altimmune"). Pursuant to the Merger Agreement the Issuer assumed all outstanding options to purchase shares of Altimmune capital stock on a 0.749106:1 basis upon closing of the merger.
Remarks
Senior Vice President of Clinical Research and Development